Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Anticoagulant management in an antithrombin-deficient pregnant woman with a history of venous thromboembolism : a case report
Avtorji:ID Kozak, Matija (Avtor)
ID Vižintin Cuderman, Tjaša (Avtor)
ID Božič Mijovski, Mojca (Avtor)
ID Lučovnik, Miha (Avtor)
ID Miklič, Marko (Avtor)
ID Tratar, Gregor (Avtor)
ID Rojnik, Tamara (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,54 MB)
MD5: 1D2B9BDBDDA6CE9FF772EF39149E7F5E
 
URL URL - Izvorni URL, za dostop obiščite https://link.springer.com/article/10.1186/s12959-025-00775-z
 
Jezik:Angleški jezik
Tipologija:1.03 - Drugi znanstveni članki
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Background: Antithrombin deficiency (ATD) in pregnant patients significantly increases the risk of venous thromboembolism (VTE), but guidelines for managing anticoagulation during pregnancy, labour, and postpartum in patients with ATD are limited. Case presentation: A pregnant woman with ATD suffered recurrent VTE in the 20th week of pregnancy despite therapeutic doses of low-molecular-weight heparin (LMWH). The acute VTE was treated with argatroban and then with warfarin until delivery. LMWH with antithrombin (AT) concentrate was introduced before and shortly after delivery, followed by warfarin, which was continued also postpartum. No further complications occurred during the remainder of pregnancy, delivery, and two-year follow-up. Conclusion: Our case highlights the challenges of anticoagulant treatment in pregnant patients with ATD. Standard weight-based LMWH dosing can lead to inadequate anticoagulation, as demonstrated by an acute VTE event in our patient. In our case, the use of argatroban proved to be safe and effective in the acute setting, followed by warfarin in the 2nd and 3rd trimester, and subsequent co-administration of LMWH and AT concentrate before and after delivery. Concomitant use of LMWH and AT concentrate allows for achieving target anti-Xa levels. Measurement of both anti-Xa and AT activity is advisable in this scenario to ensure reliable anticoagulant management. ATD is a heterogeneous disorder; therefore, each successfully managed pregnancy advances clinical practice.
Ključne besede:anticoagulants, antithrombin III, case report, pregnancy, venous thromboembolism
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1-6
Številčenje:Vol. 23, article no. ǂ94
PID:20.500.12556/DiRROS-24624 Novo okno
UDK:616.1:618.3
ISSN pri članku:1477-9560
DOI:10.1186/s12959-025-00775-z Novo okno
COBISS.SI-ID:252391171 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 9. 10. 2025;
Datum objave v DiRROS:09.12.2025
Število ogledov:99
Število prenosov:44
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Thrombosis journal
Skrajšan naslov:Thromb J
Založnik:BioMed Central
ISSN:1477-9560
COBISS.SI-ID:2611220 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0308-2019
Naslov:Ateroskleroza in tromboza

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Nazaj